Health

Takeda inks value-based rebate deal for lung cancer drug


In another bid to address the cost of prescription medicines, Takeda Pharmaceuticals (TAK) and 32PointHealth have reached a deal in which the drug maker will offer a “significant rebate” for a lung cancer treatment if the medication proves ineffective for patients.

Specifically, the deal involves Alunbrig, which is approved to treat non-small cell lung cancer. If a patient covered by 32PointHealth — the second-largest health plan in New England — does not remain on the drug for three months or more due to effectiveness or tolerability, Takeda will return an unspecified amount of money to the insurer. The drug has a $17,000 list price for a month’s treatment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED


Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button